NCT05918978 - Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

August 15, 2024

Study Completion Date

August 15, 2024

Conditions

Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome

Interventions

DRUG

Efgartigimod

Participants will receive efgartigimod IV 10 mg/kg open label, respectively.

Trial Locations (9)

Johns Hopkins University, Baltimore

University Hospitals, Neurology Clinical Trials, Cleveland

North Shore University HealthSystem, Glenview

Apex Trials Group, Fort Worth

Pioneer Clinical Research, Rosharon

Metrodora Institute, West Valley City

UC Sand Diego Sulpizio Cardiovascular Center, La Jolla

Standford Movement Disorder Center, Palo Alto

Brigham and Women's Hospital, Boston